Centessa Pharmaceuticals (CNTA) Free Cash Flow (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Free Cash Flow of -$72.2 million for Q1 2026, down 26.16% year-over-year from -$97.8 million in Q1 2025, and down 29.39% on a QoQ basis from -$55.8 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Free Cash Flow data on file, last reported at -$72.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 26.16% year-over-year to -$72.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$209.0 million (down 29.0% YoY) and the FY2025 annual result came in at -$194.2 million, down 36.67% from the prior year.
- Free Cash Flow declined to -$72.2 million in Q1 2026 per CNTA's latest filing, from -$55.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$21.4 million in Q3 2024 and bottomed at -$72.2 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$44.1 million (2023), against an average of -$45.3 million.
- The widest annual swing landed in 2022, when Free Cash Flow slumped 330.58%; it then jumped 44.67% in 2025.
- Tracing CNTA's Free Cash Flow over 5 years: stood at -$52.2 million in 2022, then jumped by 40.48% to -$31.1 million in 2023, then tumbled by 37.72% to -$42.8 million in 2024, then slumped by 30.42% to -$55.8 million in 2025, then decreased by 29.39% to -$72.2 million in 2026.
- Per Business Quant, the three latest CNTA Free Cash Flow figures stand at -$72.2 million (Q1 2026), -$55.8 million (Q4 2025), and -$58.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -72.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.22 Mn |
| Mar 31, 2026 | -72.22 Mn |
| Dec 31, 2025 | -55.82 Mn |
| Dec 31, 2025 | -55.82 Mn |
| Sep 30, 2025 | -58.55 Mn |
| Sep 30, 2025 | -58.55 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Jun 30, 2025 | -22.45 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Mar 31, 2025 | -57.25 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Sep 30, 2024 | -21.42 Mn |
| Sep 30, 2024 | -21.42 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Jun 30, 2024 | -40.58 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | -31.08 Mn |
| Dec 31, 2023 | -31.08 Mn |
| Sep 30, 2023 | -37.44 Mn |
| Sep 30, 2023 | -37.44 Mn |
| Jun 30, 2023 | -44.07 Mn |
| Jun 30, 2023 | -44.07 Mn |
| Mar 31, 2023 | -47.93 Mn |
| Mar 31, 2023 | -47.93 Mn |
| Dec 31, 2022 | -52.22 Mn |
| Dec 31, 2022 | -52.22 Mn |
| Sep 30, 2022 | -39.10 Mn |
| Sep 30, 2022 | -39.10 Mn |
| Jun 30, 2022 | -60.11 Mn |
| Jun 30, 2022 | -60.11 Mn |
| Mar 31, 2022 | -50.26 Mn |
| Mar 31, 2022 | -50.26 Mn |
| Dec 31, 2021 | -56.49 Mn |
| Dec 31, 2021 | -56.49 Mn |
| Sep 30, 2021 | -33.22 Mn |
| Sep 30, 2021 | -33.22 Mn |
| Jun 30, 2021 | -33.91 Mn |
| Jun 30, 2021 | -33.91 Mn |
| Mar 31, 2021 | -11.67 Mn |
| Mar 31, 2021 | -11.67 Mn |
| Dec 31, 2020 | -3.28 Mn |
| Dec 31, 2020 | -3.28 Mn |
| Sep 30, 2020 | -1.90 Mn |
| Sep 30, 2020 | -1.90 Mn |